1	
2	
3	
4	"but I know something's not right here":
5	Exploring the diagnosis and disclosure experiences of persons living with ALS
6	
7	Kathleen M. Foldvari ¹
8	Paul Stolee ^{1,2}
9	Elena Neiterman ¹
10	Veronique Boscart ¹
11	Catherine Tong ¹
12	
13	¹ School of Public Health Sciences, University of Waterloo, Waterloo, Canada
14	
15	
16	
17	
18	
19	² Corresponding author
20 21	Address for Correspondence: Dr. Paul Stolee, School of Public Health Sciences, University of Waterloo, Waterloo, Canada, N2L 3G1
22	E-mail: stolee@uwaterloo.ca

23 Abstract

24

24							
25	Background: Amyotrophic Lateral Sclerosis (ALS), an incurable motor neuron disease,						
26	primarily affects those between the ages of 60-79, and has an approximate post-diagnosis life						
27	expectancy of only two to five years. The condition has an unpredictable but ultimately terminal						
28	trajectory that poses a number of challenges for patients, caregivers and healthcare providers.						
29	While the diagnosis and disclosure are critical periods for intervention and support, knowledge						
30	regarding the relational, communicational and psychodynamic forces that occur within the						
31	process of diagnostic disclosure is relatively limited.						
32	Objectives: The purpose of this study was to explore the experiences of persons living with						
33	ALS in the diagnosis and disclosure of the condition, and the experiences of their caregivers.						
34	Methods: We conducted a focus group and in-depth individual interviews with Canadians living with						
35	ALS ($n = 9$), family caregivers ($n = 7$), a professional caregiver ($n = 1$), and one past caregiver (1). The						
36	interviews were transcribed, cleaned, and anonymized, and then entered into NVivo 11 for thematic						
37	analysis.						
38	Results: Participants discussed the diagnosis process, including the inklings and subtle changes						
39	prior to diagnosis, attempts at self-diagnosis, and the lengthy assessment process. Time was also						
40	a consideration in the disclosure process, in which participants shared how the diagnosis						
41	disclosure was the product of longstanding conversations with their care providers. It was						
42	described as rarely a shock to finally have confirmation. Additionally, participants shared their						
43	information seeking strategies and needs for a diagnosis that, for them, typically came with						
44	insufficient information on the disease, prognosis, and next steps.						

45	Significance: This project serves as an initial step in bridging the relevant gaps in our knowledge
46	and understanding towards improved patient-centered care practices in the diagnosis and
47	disclosure of ALS.
48	
49	
50	Keywords: Amyotrophic Lateral Sclerosis (ALS), Diagnostic Disclosure, Qualitative methods,
51	Caregivers
52	
53	
54	
55 56	
57	
58	
59	
60	
61	
62	
63	
64 65	
65 66	
67	
68	
69	
70	
71	
72	
/3 74	
74 75	
76	
77	
78	
79	
80	
81	
82	

83 Introduction

84	ALS is a progressive and incurable multi-system disorder characterized by muscle						
85	wasting, severe disability, and unpredictable illness trajectories. Its symptoms are caused by						
86	rapid brain and spinal cord nerve cell degeneration, and typically lead to death within three						
87	years of initial symptom onset [1-3]. ALS is a burdensome and typically terminal disease that						
88	causes great stress and uncertainty for the individual with the disease, and all those in their circle						
89	of care [4-6].						
90	At present, there are approximately 200,000 people globally who are living with ALS						
91	[7], and it is predicted that the global incidence of ALS will increase nearly 70% by the year						
92	2040 [8]. This anticipated increase in diagnosed cases of ALS has been attributed, largely, to the						
93	aging of the population. The number of older adults, worldwide, is expected to reach two billion						
94	by 2050 [9]; ALS is classified as an "age-dependent neurodegenerative disease" [10]. The ALS						
95	rate of incidence peaks around the eighth decade of life, while the majority of those living with						
96	the condition are between the ages of 60-79 years [8,10-12].						
97	A lack of familiarity with the unique nature of ALS limits healthcare providers in being						
98	able to answer patients' questions and direct their care appropriately. This lack of knowledge						
99	about the condition has the potential to create gaps in the continuity of care starting with						
100	diagnosis [2,13-15]. ALS' relentless attack on the body's physical functioning, as well as its						
101	incurable nature, make the disease an unfavorable diagnosis. People are reported to respond to						
102	hearing a diagnosis of ALS with a range of emotions. It is not unusual for patients to experience						
103	initial shock and distress, anger or worry [16-19]. As is true for many people faced with bad						
104	news about their health, it is common for people to struggle emotionally. Experiences with						
105	denial or wishful thinking throughout the disease course are also common reactions that are						

106	recognized in the literature [20-23]. Some studies suggest that more attention ought to be paid to
107	patients' emotional coping needs, as their emotional coping can have a significant impact on
108	how they are able to engage in health planning related to their overall health outcomes
109	[16,18,21,24,25]. In response to such evidence, general guidelines for diagnostic disclosure have
110	been developed and implemented to help healthcare providers effectively deliver bad news to
111	their patients, while identifying and dealing with unfavoured coping mechanisms such as denial,
112	e.g., [14,17,18]. Though well received, many of the current guidelines were not developed or
113	tested specifically for use in ALS care. When it comes to communication and relational care,
114	current practices in ALS care are, and have typically been, guided by parameters outlined for
115	cancer care focused initiatives [20,26-28].

116 **The diagnosis of ALS**

Diagnosing ALS is typically a very involved process, as there is no one test that can determine, with certainty, whether or not the presented symptoms are related to the disease [2,13,19]. The *El Escorial* criteria for the diagnosis of ALS, originally developed in 1990 by the World Federation of Neurology and updated in 2000, are applied worldwide by clinicians and scientists in efforts to identify and classify symptoms of the disease as they are related to either upper or lower motor neuron degeneration [29].

In Canada, primary care physicians are usually a patient's first point of contact with the healthcare system [30]. For ALS patients, and those presenting with possible symptoms of the condition, primary care services offer referral and access to multidisciplinary care clinic teams that ideally work in a coordinated way to facilitate the diagnostic process, help guide efforts in

127 symptom management, and support the prevention of medical complications and premature128 death [24,30-32].

129 A patient's journey often begins with complaints of preliminary symptoms such as: 130 muscle cramps, weakness and fatigue. Shortness of breath, numbness, and/or tingling in the 131 extremities are also common first symptoms. After noticing these first symptoms, patients will 132 seek out a primary care physician to help make sense of their symptoms and consider their case. 133 The primary care physician will then make a referral to a specialized neurologist for testing and 134 disease confirmation, if appropriate. Once ALS has been confirmed through the reasonable 135 exclusion of other conditions, the patient's specific needs are assessed and a care team is 136 assembled [1,24,31,32].

A confirmed diagnosis is often a prerequisite to gaining access to specialized and funded services, such as specialized ALS clinics. A confirmed diagnosis can take upwards of a year, and misdiagnosis is relatively common in the initial stages of the process [1,2,13]. The often-convoluted process of arriving at a confirmed diagnosis of ALS can often affect patients' relationships with their care providers, and thus their overall satisfaction with their care, making good communication an essential part of the process [1,33,34].

143

The diagnosis disclosure of ALS, a critical period for intervention

While a diagnosis is defined as the "the art or act of identifying a disease from its signs and symptoms" [35], diagnostic disclosure specifically refers to the act of sharing the diagnosis with the patient and/or caregivers. Diagnostic disclosure is a term typically used when a clinician is disclosing diagnoses with serious and long-term implications, such as dementia or autism [36]. Most tools and guidelines currently available for diagnostic disclosure do not offer specific

149	instructions for how to go about disclosing the diagnosis of ALS towards successful coping
150	[24,26,37], although Pizzimenti and colleagues [18] do offer some guidance on the timing,
151	location and communication of the diagnosis. Despite some existing guidance, a large number of
152	physicians report experiencing a great deal of stress and uneasiness when breaking the news of
153	terminal illness to patients. Meanwhile, many patients say that they are left feeling under-
154	informed and dissatisfied after hearing the news [38-40]. There is still a need for practice-level
155	improvements to be made to the disclosure process for ALS [38,41].
156	As a sensitive and stressful step in the care process, diagnostic disclosure is a critical
157	period for intervention which is potentially predictive of future coping-related outcomes
158	[40,42,43]. There is likely to be great benefit in working towards improving current guidelines
159	and recommendations by expanding our knowledge base about peoples' experiences in the
160	process.

161

Past & present approaches to diagnostic disclosure

162	Two commonly used tools for the diagnostic disclosure of serious conditions include the
163	six-step SPIKES protocol, described by Baile et al. [20], and the parameters outlined by
164	Andersen et al. [24] of the European Federation of the Neurological Societies (EFNS) task force.
165	The SPIKES protocol lays out a series of steps to be followed during conversations in which bad
166	news is delivered. These steps are aimed at guiding healthcare providers in gathering
167	information, transmitting relevant information, providing support, and encouraging patients'
168	engagement in care planning [20]. The EFNS task force lists a number of recommendations to be
169	considered prior to and during conversations in which a diagnosis of ALS is to be relayed.
170	Among the recommendations listed are: a comfortable quiet setting in which to communicate the

bad news; an understanding of who the patient is, and what their communicational preferences
are, prior to disclosure; and the use of simple and carefully worded statements [24]. This is not
dissimilar to the recommendations made by Pizzimenti et al. [18], specific to the disclosure of
ALS.

175	Both tools (SPIKES and EFNS) have been correlated with improvements in patients'
176	satisfaction surrounding the manner in which the news of their illness was broken to them [38-
177	40]. However, many physicians still report experiencing a great deal of stress and uneasiness
178	when breaking the news of terminal illness to patients, while patients are left with many
179	questions about their condition [38,41,44,45]. This literature suggests that parameters for
180	diagnostic disclosure tend to be vague and do not meet expectations for supporting healthcare
181	providers in facilitating conversations that focus on outcomes, rather than just treatment options,
182	with their patients. This creates a risk for negative experiences in both care provision and on the
183	receiving end [24,38,44,46,47].

184

A deeper understanding of varying ALS care experiences could lay the foundation for improving the diagnostic and disclosure process, potentially leading to improved coping and quality-of-life [18,38,40,41,43]. The current study seeks to understand the experiences of diagnosis and disclosure of persons living with ALS, with the support from their caregivers.

189

9 Materials and Methods

We utilized a qualitative interview approach to capture participants' experiences in
diagnosis and disclosure of ALS [48-50]. Data collection took place in Southern Ontario,
Canada, from October 2017 to June 2018.

193 Eligibility & recruitment

194	Patients diagnosed with the various ALS types, as well as caregivers, were eligible. No						
195	participants were excluded based on their gender, socio-economic status, race, ethnicity or						
196	religious affiliation. Though the median age for ALS symptom onset is about 62 years of age,						
197	most people who develop ALS are between 40 and 70 years [8,12,51]. This study thus sought to						
198	collect data from and about adults (both male and female) roughly within the indicated age range						
199	and beyond; this study was not restricted to patients living with ALS at ages conventionally						
200	defined as "older" (i.e., 65+). The eligibility of caregivers to participate in the study was based						
201	on self-report of their involvement in the care of someone diagnosed with ALS, whether they						
202	were a partner, family member, or friend.						
203	This study received ethics clearance from the University of Waterloo Office of Research						
204	Ethics [ORE # 22512]. In the role of a gatekeeper [52], the ALS Society of Canada shared our						
205	recruitment materials (emails and recruitment posters) with potentially eligible individuals.						
206	Data collection						
207	In October 2017, a group of three patients living with ALS and six caregivers						
208	participated in an audio-recorded focus group interview in which participants discussed their						
209	experiences with diagnosis and disclosure. The focus group participants also helped develop the						
210	interview guides for subsequent individual interviews; these included one interview guide for						
211	use with patients and a second for use with caregivers.						
212	In the Spring of 2018, thirteen participants were recruited to participate in semi-						
213	structured interviews [48]; this included four individuals who had also participated in the initial						
214	focus group. Between the focus group and individual interviews, a total of 18 unique individuals						
215	participated in this study. Interviews took place at the time and location of the participants'						

216	choosing and were conducted over the telephone or in-person. Individual and dyad interviews
217	were conducted based on the indicated preferences of the participants. Upon receipt of written
218	informed consent, interviews were audio-recorded, and later were manually transcribed verbatim
219	by the lead author. In the interviews, participants discussed their diagnosis and diagnostic
220	disclosure experiences and provided demographic information. The lead author also composed
221	field notes throughout the data collection period (October 16, 2017 to June 20, 2018). This study
222	was limited in time and scope, and saturation or "data adequacy" [53] may not have been
223	achieved.

Description of sample

The average age of participants with ALS was 55 years, ranging between approximately 30 to 70 years (rounded for anonymity). The average age of all caregiver participants was 44 years, ranging between approximately 25 and 60 years (rounded for anonymity). The average age of caregivers, as stated, represents all types of caregiver participants in the sample excepting one family caregiver who declined to complete the demographics form. All participants lived in southern Ontario, except one who lived in British Columbia and completed their interview remotely.

The majority of the participants with ALS or similar diagnosis were male, while the majority of the caregiver participants (including past and professional) identified as female. Participants reported diagnoses of various types and motor neuron disease (MND) sub-types including probable/ atypical ALS, confirmed ALS, confirmed PLS (one person with Partial Lateral Sclerosis (PLS), a motor neuron disease similar to ALS, participated in the focus group interview), confirmed ALS – slow progressing, with some overlap between categories, where

238	participants were given more than one related diagnosis. The overlap is attributed to initial
239	misdiagnoses and/or multiple opinions from different healthcare providers. Participants spoke to
240	their unique experiences identifying with the ALS diagnosis and its sub-types as they received
241	opinions from various healthcare providers. These diagnoses were reported to have occurred
242	between the years of 2010 to 2017. All participants described a path to diagnosis that began with
243	either a visit to a family doctor or walk-in clinic physician upon symptom onset, followed by a
244	referral to an ALS clinic for specialized diagnostics and care Final ALS diagnoses were made by
245	specialized neurologists. See Tables 1 and 2 for participants' summaries; summaries edited for
246	confidentiality.

247 Table 1. Participant Sample Summary (Focus Group Interview), n=9

Gender	Role/ Relationship	~Age	Loc ale	Interview Format	Approximate Date/ Nature of Diagnosis
F	Caregiver – Professional	40	Large Urban City (Greater Toronto Area), ON	Group	
F	Past Caregiver – Daughter	45	Small Town (Waterloo Region), ON	Group	
F	Person living with PLS	65	Small Town (Waterloo Region), ON	Group	2017 – Confirmed/ PLS
F	Caregiver – Daughter	35	Small Town (Waterloo Region), ON	Group	
F	Caregiver – Sister	Declined to answer	Declined to answer	Group	
F	Person living with ALS	45	Medium City (London Metro Area), ON	Group	September 2015 – Confirmed/ Slow progressing
M	Caregiver – Boyfriend	45	Large Urban City (Greater Toronto	Group	

			Area), ON		
М	Person living with ALS	55	Large Urban City (Kitchener Metro Area), ON	Group	Spring 2016 – Confirmed/ Progressed ALS
F	Caregiver – Cousin	50	Large Urban City (Kitchener Metro Area), ON	Group	

248

249Table 2. Participant Sample Summary (Individual and Dyad Interviews), n=13

Gender	Role/ Relationship	~Age	Locale	Interview Format	Approximate Date/ Nature of Diagnosis
М	Person living with ALS	65	Large Urban City (Kitchener Metro Area), ON	Individual	October 2016 – Probable/ Atypical
М	Person living with ALS	30	Large Urban City (Greater Vancouver Area), BC	Individual	May 2016 – Confirmed/Limb onset
F	Person living with ALS	55	Large Urban City (Kitchener Metro Area), ON	Dyad	2015/2016 – Confirmed
М	Caregiver – Son	25	Large Urban City (Kitchener Metro Area), ON	Dyad	
М	Person living with ALS	60	Large Urban City (Greater Toronto Area), ON	Individual	2015 – Confirmed/ Atypical; Lower MND Variant
Μ	Person living with ALS	50	Large Urban City (Kitchener Metro Area), ON	Dyad	Spring 2010 – Confirmed/ Slow progressing
F	Caregiver – Wife	50	Large Urban City (Kitchener Metro Area), ON	Dyad	
F	Caregiver – Wife	60	Large Urban City (Kitchener Metro Area), ON	Individual	
F	Person living with ALS	70	Large Urban City (Kitchener Metro Area), ON	Individual	2010 – Confirmed/ Slow progressing

F	Person living with ALS	45	Medium City (London Metro Area), ON	Dyad	September 2015 – Confirmed/ Slow progressing
М	Caregiver – Boyfriend	45	Large Urban City (Greater Toronto Area), ON	Dyad	
М	Person living with ALS	55	Large Urban City (Kitchener Metro Area), ON	Dyad	Spring 2016 – Confirmed/ Progressed ALS
F	Caregiver – Cousin	55	Large Urban City (Kitchener Metro Area), ON	Dyad	

250

251 Analysis

252 Data were cleaned, anonymized, and then uploaded to NVivo 11 for analysis. A 253 thematic analysis, as outlined by Braun & Clarke [54] was used. The thematic analysis 254 conducted for the purposes of this project aimed to understand the experiences of persons with 255 ALS through the eyes of patients and their caregivers and took place under epistemological 256 assumptions aligned with the constructionist paradigm. Under this system of belief, themes were generated through an analysis of participant-described events and incidents, with the 257 understanding that people build their own realities as they navigate through, and create 258 259 meaning from, the world around them. The constructionist paradigm recognizes and embraces 260 the complexity of human life, which provided a suitable basis for understanding people in their 261 attempt to cope with a terminal illness: 'what they do' and 'how they do it' [54,55]. The data 262 analysis process occurred inductively, meaning that the researcher did not attempt to fit the data 263 into an existing framework or hypothesis, but rather let the data 'tell the story' [54].

Our analysis process included the lead author reading the transcripts twice, specifically looking for patterns in the second reading; identifying codes that represented the data, and then using printed copies of the codes to visually organize the codes thematically; defining each

267	code, and sharing these code definitions with co-authors for review; additional readings of the
268	transcripts and line-by-line coding in NVivo 11, and then isolating the most significant themes.
269	These themes were then shared with the study participants. All participants were presented with
270	summaries of the themes and asked to confirm or refute the findings.

271 Strategies for rigor

272	Strategies for rigor [56] included member checking to verify research findings, research team
273	debriefing, triangulating data and themes from different participant groups (e.g., caregivers and persons
274	living with ALS), and keeping detailed field notes during data collection. Regular notetaking was used
275	by the lead author to reflect on her perceptions, preconceptions, beliefs and values, and to attempt to
276	separate her personal experiences with ALS from those of the participants.

277

278 **Results**

Findings are clustered into two overarching themes, the first on participants' path to diagnosis, and the second on participants' diagnosis disclosure experience, and accompanying needs. In both themes, time and lengthy intervals were noted.

282 The path to diagnosis: inklings and assessments

283	Participants disclosed that their path through diagnosis was initiated by changes in
284	functional capacity or unusual sensations. For example, one participant with ALS said:
285	
286	"Before [I was diagnosed] it was about my blood sugarThe family doctorwas
287	sending me for measurements of my blood sugarone dayI was trying to do

288 289	push-upsand I couldn't do it. I couldn't do it anymoreso, that was when I went to [my family doctor]" — [Person living with ALSI-1]
290	
291	Participants described a series of events triggered by their initial symptoms that
292	involved a visit to either their family doctor or a doctor at a walk-in clinic. It was indicated
293	that this visit instigated initial tests ordered by the doctor, and processes of theory generating
294	and self- diagnosis. These processes are reflected in the following statement made by a
295	participant with ALS:
296	
297 298 299 300 301 302 303 304 305	 "I started to feel like I was being electrocuted in my feet and legs it just went from my toes to my knees. And then as time continued to pass[it was] moving up my body I pushed the doctor to give me a possibility of what it could be because I was getting a little bit frustrated. Andmy wife and I had been reading tens of dozens of articles on the Internet; and gone back and forth to each other trying to cross-reference my symptomswe came up with all sorts of things" — [Person living with ALSI-5] Both patients and doctors seemed to have been speculating as to what might be
306	causing the symptoms, as illustrated by the statement above, as well as the following remarks
307 308	made by a person living with ALS and a caregiver, respectively:
309 310 311 312	"I was atypical, healthy guy and noticed some atrophy in my left hand. Specifically in the muscles that control the thumbI was a cliché quote, unquote, muscly kind of dudeI assumed that I pinched a nerve in my arm while exercising or something like that" — [Person living with ALSI-2]
313314315316317	" initially, the degree of weakness was so mildthat's why I thought that it would be something elsein terms ofweight lossthey were just thinking his nutritional status was not very good[that] he wasn't getting enough proteinThen they [thought]maybe other conditions also cause weight loss symptoms"— [CAR1-8]

318	The conversations surrounding the first symptoms presented to participants' primary
319	care physicians (or first points of contact) involved a lot of back and forth in testing, and
320	referral to various specialists, otherwise characterized as a lengthy process of trial and error.
321	As one participant with ALS indicated: "it was a bit of a revolving doorof characters
322	who sort of confirmed my diagnosispeople in and out" [Person living with ALSI-2]. In
323	some cases, misdiagnosis and ineffective surgery or treatment aimed at symptom
324	management were also experienced. One participant with ALS said: "[It was] all just sort of
325	symptom management while we were trying to figure out what the problem was and once
326	targeted we could treat ithopefully" [Person living with ALSI-5].
327	Others stated:
328 329 330 331 332	"my hands started getting weak. I could barely turn the keys to unlock my car. So, I went to the doctor and they said, something's not right And then[the doctor] said: "I think you have carpal tunnel". So they did the surgery on both hands and that didn't really helpThen that doctor said it must be something different" — [Person living with ALSI-9]
333 334 335 336 337 338	"I was a PSW [personal support worker] and I fell in the bathtubit was drop footand I knew something wasn't rightWhen I fell in that bathtub, I was fine. I could run and jump until I fell in that bathtubI kept workingand then I went to [the doctor]and I was getting acupuncture. For many years I kept going and trying different things all the time" — [Person living with ALSD-3]
339	The initial back and forth was ultimately followed by a determination, through a
340	process of elimination, that the presented symptoms were most likely neurological in nature.
341	This is said to have prompted final referrals made either to first, a local neurology specialist,
342	or directly to a major city clinic neurologist for similar assessments and observations of
343	symptom progression. One participant with ALS asserted: "basically they rule everything
344	out, and then as you continue to get worse, they say: "Hey, you got ALS"" [Person living
345	with ALSI-2]. Two other participants explain similar experiences:

346	
347 348 349 350 351	"it's not an obvious thing, like you're going to break a leg, where you go into any ER and they put a cast on you, and you're out the door type of thing. When it is a diagnosis of exclusion and you don't know what it isyou got to figure out what it is or what it isn't" — [Person living with ALSI-5]
352 353 354 355 356	"they try to rule out everything else. Then they say you probably have ALS. But, [they] refer [me] to a team in [a major city]and they basically did the same tests, and said the same thing: that I probably have ALS. Then they said about nine months later they would follow-upand then they said: "okay, you have ALS". — [Person living with ALSD-6]
357	
358	This led some directly to acceptance, while others sought a second opinion first:
359	
360 361 362 363	"I went to [the clinic]I [told] them, I don't know what I have. I don't know if I have ALS or what I have. So, I asked for a second opinion and they said I had a neurological disease. So I said, I don't know what I have, but I know something's not right here" — [Person living with ALSD-3]
364	
365	Overall, the process of diagnosis was described by participants as one characterized by
366	a great deal of back and forth, frustration, and hopeful theorizing. Participants indicated
367	putting a great deal of effort into ascertaining a label that best suited the symptoms that they
368	were experiencing.
369	
370 371	The diagnostic disclosure process: intervals and information
372	For the participants in this study, all conversations surrounding diagnosis and
373	prognosis were conducted in-person, regardless of the healthcare provider that was relaying
374	the information. These conversations were indicated to have typically gone on for nine

375	months to about a year. In two cases, a confirmed diagnosis was reached after two to three
376	years:
377	
378	"there was maybe a yearmaybe nine months of activity before [I received a
379	confirmed diagnosis]but that's the day essentially, that they exhausted all of
380	treatments and were monitoring my progression. Then they essentially concluded
381	and voiced to me that I had ALS" — [Person living with ALSI-2]
382	"I think it wasn't until [three years later] that we were really told: "Okay, at this
383	point between three different hospitals, we have run every conceivable testand
384	in the absence of finding anything else that we could pin this on we have to
385	conclude that you have lower motor neuron onset ALS"" — [Person living with
386	ALSI-5]
387	
388	On the other hand, a confirmed diagnosis was reached after a matter of weeks for
389	another case.
390	The process of receiving a confirmed diagnosis was described as not coming as a
391	surprise, but as confirming the suspected, based on the patients' own research. This is
392	reflected in these quotes from persons living with ALS:
393	
394	"and between the first neurologist and the second I had done a lot of
395	research, so I had already decided that's what I had. So, it wasn't a surprise"
396	[Person living with ALSI-5].
397	
398	"I was hoping for good news, but at the same time I wasn't completely
399	surprised about the bad newsgiven the independent study I didI've
400	always had terrible luck. So right off the bat and given me reading the
401	Wikipedia page and noticing the physical symptoms I sort of concluded
402	independentlyand with my pessimismthat I had ALS. But yeah, I was
403	noticing continued muscle atrophy, continued weakness, gradual, but obvious.
404	over those nine months. And when I finally got the word what it was, it was
405	one of these things that I had been expecting to hear I think" — [Person living
406	with ALSI-2]
407	

408	After receiving a confirmed diagnosis, participants described a subsequent process of
409	convening a multidisciplinary care team. For example, one person living with ALS says:
410	"once I got a confirmed diagnosis from the specialized ALS clinic, it's been a whole care
411	team of a half dozen individuals that I see quite regularly" [Person living with ALSI-2].
412	Participants perceived their concrete diagnosis as pivotal, such that it sparked a will to push
413	forward and reassess personal priorities, such as for this participant who declared: "I can't go
414	anywhereI have too much to live for!" [Person living with ALSD-3].
415	Similarly, this person living with ALS shared:
416	
417	"So essentially what happened from that day forward it's like: okay, well, you
418	have three to five years or whatever math they give youand pardon my
419	language, but it's like: fuck that! I'm not going in the office anymore. You know
420	what I mean? Like what's in it for me?" — [Person living with ALSI-2]
421	
422	In trying to digest the diagnostic and prognostic information that was presented to
423	them, participants said that they took it upon themselves to educate themselves about their
424	condition:
425	
426	"So I told [my wife] that night when I got home from work. Andwhen we went
427	to bed, we started looking it up on the Internet. And that's how we realized that's
428	all we had for those six weeks [until our next appointment]" — [Person living
429	with ALSD-6]
430	
431	Participants criticized the healthcare system for long waits between appointment times
432	and complained that one of their most significant struggles in the diagnostic disclosure
433	process was the limited amount of information provided about the condition they were just

434	diagnosed with. One person living with ALS stated: "I knew what I had when I went to the
435	first neurologistwhen she told me I probably have ALS. But, I didn't even know what that
436	was, and she wouldn't tell me" [Person living with ALSD-6]. In this case, the participant
437	expected to receive information and education about their condition from their neurologist.
438	Instead, the neurologist gave the person pamphlets and told the person to "go home and look
439	it up on the Internet". Their caregiver added: "when you first read [the pamphlets they give
440	you]it's sickening. You just read what it isyou don't know. Just to be thrown [the
441	information], with no lead up to it is awful" [CARD-7]. This scenario highlights the lack of
442	familiarity and discomfort with ALS diagnosis disclosure and its direct impact on patient
443	care.
444	Participants discussed that having a concrete diagnosis was helpful, in that it granted
445	them access to support from social organizations such as local ALS Society of Canada
446	chapters and home and community care services, and eligibility to participate in treatment
447	trials and clinical studies:
448	
449 450 451	"I am going to be trying that new medicinehopefully in the next few weeks[through the ALS clinic]So I was waiting for the phone call today[from the ALS clinic neurologist]" — [Person living with ALSD-3]
452	"we filled out a million formsSo I'm now on the wait list for an interview
453	fordirect funding. And I now havethrough [the local health authority], doing
454	personal support hours one hour daily. Which basically is: come in make me a
455	coffee, shower meCool. I'm hooked up with [the local hospice], but I haven't
456	heard back from them yet" — [Person living with ALSD-10]
457	
458	Generally, experiences of diagnostic disclosure were described as not a
459	surprise or a shock. Participants described having been grateful to be through the

diagnosis process, such that they were then able to begin to focus on establishing nextsteps and understanding care and treatment options with a consistent care team.

462 **Discussion**

463 Current recommendations for diagnostic disclosure, as laid out by Baile et al. [20] and 464 Andersen et al. [24], advise verbal in-person sharing of diagnosis and prognostic information. 465 According to participants, this is indeed the way such conversations are typically carried out. Participants did not share evidence to suggest that healthcare providers were implementing 466 467 recommendations such as offering an invitation to share information or exploring emotions as 468 in the SPIKES protocol and EFNS task force report [20,24]. However, the general process of 469 care as described in the literature was corroborated by the findings of this study. Persons with 470 ALS and caregivers in the current study explained that their journeys through the care system 471 began with the presentation of mild symptoms to a primary care physician, followed by a 472 diagnostic process of elimination, and a referral to a neurologist, a neurology specialist, or an 473 ALS clinic team in a major city. A formal diagnosis from a neurologist provided them access 474 to specific supports. This path is consistent with the descriptions of multiple sources both in 475 and outside of Canada [1,15,24,31,32]. Our findings are also consistent with the work of 476 Hogden et al. [16] who determined that the nature of the terminal prognosis associated with ALS can make it difficult to manage dynamics in providing and receiving healthcare, as well 477 as patients' engagement in their care. 478

479 Most participants in our study were not surprised by their diagnosis at the point of 480 formal disclosure. Participants indicated that after having gone through a lengthy process of 481 trial and error, and having done their own theorizing and research throughout, receiving 482 confirmation of their diagnosis did not come as a shock, in contrast to the findings of some

483 prior studies. For example, Hogden et al. [16] reported that health professionals described 484 patients as being shocked by the diagnosis of ALS and as having difficulty accepting it. These 485 reactions were seen as delaying the provision of additional information and the 486 commencement of care planning. The same research group studied the perspectives of 487 patients' experiences of receiving an ALS diagnosis, again finding that shock was a common 488 reaction [57]. On the other hand, several patients in the latter study indicated that the 489 diagnosis was not a surprise, but a confirmation of their own conclusions [57], which was 490 consistent with experiences described by participants in our study.

491 Emotions of surprise and shock have been studied in the experiences of people 492 receiving a cancer diagnosis. Plage and Olsen [58] studied the illness narratives of people 493 living with cancer and found that surprise and shock (as an intense form of surprise) conveyed 494 the implication that the diagnosis of cancer for those expressing surprise was unexpected and 495 unpreventable and thus not the individuals' responsibility. In this study, the experience of 496 surprise, or the lack thereof, for persons living with ALS, reflected a different illness 497 experience. Persons living with ALS were not surprised by the diagnosis because they had 498 been led to that conclusion by a lengthy diagnostic process and their own information-499 seeking, and not because they felt some sense of responsibility for having the condition (as 500 might be the case for a long-time smoker who is diagnosed with lung cancer).

Participants described the Internet as a significant tool in their quests to identify the cause of their symptoms. Patients and caregivers talked about doing their own research using the Internet as a tool. Participants explained that they brought the results of their searches and discussions to their healthcare providers for further consideration and conversation. The findings of Abdulla et al. [59] on information seeking behaviors on patients and their care were similar to the findings of this study, in that patients and their caregivers sought

information from multiple sources, with many relying on Internet sources for information (as
was also found by [60]), and that they wanted to share and discuss the information they found
with their healthcare providers. Conducting their own independent research seemed to offer
participants in the current study a sense of control and authority during the diagnosis process.
This information seeking behavior may have contributed to their familiarity with their
condition, enough so to avoid surprise when they received their formal diagnosis.

513 Once they received confirmation of the suspected diagnosis, participants were finally 514 able to put a name to their condition and begin exploring their treatment options. In the case 515 of this sample, it was most common for participants to experience more of an intense reaction to their initial symptoms, as they worried about their ability to continue to perform optimally 516 517 in life and at work. Participants began to reason and rationalize increasingly as they grew 518 more aware of the limited treatment options that existed for their condition; this was until they 519 slowly began to make peace with their circumstances, potentially facilitated by extended 520 rather than abrupt processes in diagnostic disclosure or confirmation.

521 Jakobsson Larsson and colleagues [14] found ALS patients to be less engaged in 522 information seeking, while continuous information seeking was quite common among persons 523 with ALS in this study. This may highlight a difference in coping needs for persons living in 524 community and patients in hospital, a setting in which knowledgeable healthcare providers 525 are typically more present and available. Participants described this as a means of informing 526 their own understanding of their condition in order to curb uncertainty, given the limited and 527 sometimes untimely information they received from healthcare providers. Participants 528 described information provision as generally lacking in their healthcare experience. However, the sense of control and autonomy that they felt in doing their own research about their 529

530	condition is consistent with the empowerment to improve disease management and decision
531	making that Pizzimenti et al. [18], talk about fostering, using communication that considers
532	the information needs and goals of patients, as well as social, culture and other personal
533	factors. It also suggests that more formal direction on where and how to seek useful
534	information may help patients engage with the diagnosis process in a way that can reduce
535	prolonged processes in coming to a diagnosis by being referred to a specialist for symptoms
536	mistaken for other conditions [15,18]. Though concerns of overwhelming patients with too
537	much information, too soon, have been discussed by research groups such as McCluskey et al.
538	[38] and Connolly et al. [39], this present study suggest that persons with ALS want more
539	information about what to expect in their condition, and about available resources, than they
540	are currently receiving [61]. It is understandable that a long period of diagnostic uncertainty
541	along with worsening symptoms would motivate persons to seek information from the
542	Internet. The well-known concerns about the limited reliability of online health information
543	[59-61], which was acknowledged by some participants in this study, heighten the importance
544	of timely information from healthcare providers.

545 As indicated by both patients and caregivers, such information would facilitate coping 546 by providing people with a platform from which to create their own plans for proactive action 547 towards better management of their current and anticipated needs.

548 **Strengths and limitations**

549 This study used multiple types of data collection (a focus group interview, individual and 550 dyad interviews). The focus group interview allowed for an initial exploration of themes, and the 551 dyad and individual interview formats were principally driven by participant preference. Great care

552	was taken to center and focus on the voice of the person living with ALS. Across these different
553	types of data collection, the themes were largely consistent. Member checking with all participants
554	was used to further ensure their voices and experiences were appropriately captured in the analysis
555	Limitations of this study include the limited reflection of the voices of older persons
556	living with ALS. Few persons with ALS over the age of 65 years participated in the study;
557	some potential participants over the age of 65 were too far progressed in their disease to
558	participate. This can be considered a limitation of the current study, as the experiences of
559	persons with ALS potentially with the highest needs were not captured. Future research
560	should give careful consideration to recruitment methods.

561 Conclusion

This project serves as an initial step in bridging the relevant gaps in our knowledge 562 and understanding toward improved patient-centered care practices in the diagnosis and 563 564 disclosure of ALS. This study has highlighted the importance of continuing, meaningful communication between patients and healthcare providers to minimize uncertainty and to 565 support care planning. Further research will be necessary to corroborate and extend the study 566 567 results. It will be necessary to incorporate the voice of healthcare providers that play a role in supporting people living with ALS and other closely related conditions, so that barriers and 568 resource limitations that they might face in trying to fulfill the needs and desires of their 569 patients can be identified. Religious-, cultural-, age-, and gender-specific needs will be 570 important areas of continued exploration. These current and future findings, together, could 571 support and improve the diagnosis and diagnosis disclosure experiences of persons living with 572 ALS, and their caregivers and providers. 573

576	
577	Acknowledgements

578	The authors gratefully acknowledge the persons with lived experience of ALS who participated in the
579	interviews for this project, and the ALS Society of Canada for their assistance with recruitment. The
580	authors also thank Veronica Sacco and Christiano Choo for their help in reviewing and editing earlier
581	versions of this paper.

582

574 575

583 **References**

584	1. A Guide to ALS Patient Care for Primary Care Physicians. [Online].: ALS-Canada; 2016.
585	Available from: https://als.ca/wp-content/uploads/2017/02/A-Guide-to-ALS-Patient-Care-For-
586	Primary-Care-Physicians-English.pdf.
587	2. Murray L, Butow PN. Advance care planning in motor neuron disease: A systematic review.
588	Palliative & supportive care. 2016; 14(4): 411-423.
589	3. Oliver D, Borasio GD, Johnston W. Palliative care in amyotrophic lateral sclerosis: From
590	diagnosis to bereavement. OUP Oxford. 2014.
591	4. de Wit J, Bakker LA, van Groenestijn AC, van den Berg LH, Schröder CD, Visser-Meily JM, et al.
592	Caregiver burden in amyotrophic lateral sclerosis: a systematic review. Palliative medicine. 2017;
593	32(1): 231-245.
594	5. Hecht MJLGE, Tigges S, Hillemacher T, Winterholler M, Hilz MJ, Heuss D, et al. Burden of care
595	in amyotrophic lateral sclerosis. Palliative Medicine. 2003; 17(4): 327-333.
596	6. Pagnini F, Rossi G, Lunetta C, Banfi P, Castelnuovo G, Corbo M, et al. Burden, depression, and
597	anxiety in caregivers of people with amyotrophic lateral sclerosis. Psychology, Health & Medicine.
598	2010; 15(6): 685-693.
599	7. ALS Canada. About ALS. [Online]. Available from: https://als.ca/what-is-als/about-als/.
600	8. Arthur KC, Calvo A, Price TR, Geiger JT, Chio A, Traynor BJ. Projected increased in
601	amyotrophic lateral sclerosis from 2015-2040. Nature Communications. 2016; 7: 12408.
602	9. World Health Organization. Ageing and health. [Online].; 2022. Available from:
603	https://www.who.int/news-room/fact-sheets/detail/ageing-and-
604	health#:~:text=By%202050%2C%20the%20world%27s%20population,2050%20to%20reach%2042
605	6%20million.
606	10. Wolfson C, Kilborn S, Oskoui M, Genge A. Incidence and prevelance of amyotrophic lateral
607	sclerosis in Canada: a systematic review of the literature. Neuroepidemiology. 2009; 33(2): 79-88.
608	11. Logroscino G, Tortelli R, Rizzo G, Marin B, Preux PM, Malaspina A. Amyotrophic lateral
609	sclerosis: An aging related disease. Current Geriatrics Reports. 2015; 4(2): 142-153.
610	12. Boyd JC, Cooper TA, O'Brian BD. The path to diagnosis for persons with ALS in Nova Scotia.
611	Dalhousie Medical Jounral. 2016; 42(2): 3-6.
612	13. Jakobsson Larsson BJ, Nordin K, Nygren I. Coping with amyotrophic lateral sclerosis; from
613	diagnosis and during disease progression. J Neurol Sci. 2016; 361: 235-242.
614	14. Richards D, Morren J, Pioro E. Time to diagnose and factors affecting diagnostic delay in
615	amyotrophic lateral sclerosis. In: Araki T, ed. Amyotrophic Lateral Sclerosis. 2021 July 25;: 15-33.
616	15. Hogden A, Greenfield D, Nugus P, Kiernan MC. Engagin in patient decision-making in
617	multidisciplinary care for amyotrophic lateral sclerosis: thew views of health professionals. Patient
618	Prefer Adherence. 2012a; 6: 691-701.
619	16. Pizzimenti A, Gori MC, Onesti E, John B, Inghilleri M. Communication of diagnosis in
620	amyotrophic lateral sclerosis: stratification of patients for estimation of individual needs. Frontiers in
(01	

621 psychology. 2015; 6: 745.

622 17. Hugel H, Grundy N, Rigby S, Young CA. How does current care practice influence the 623 experience of a new diagnosis of motor neuron disease? A qualitative study of current 624 guidelines-based practice. Amyotrophic lateral sclerosis. 2006; 7(3): 161-166. 18. Baile WF, Buckman R, Lenzi R, Glober G, Beale EA, Kudelka AP. SPIKES-A six-step protocol 625 626 for delivering bad news: application to the patient with cancer. Oncologist. 2000; 5(4): 302-311. 19. Williams AR, Olfson M, Galanter M, Assessing and improving clinical insight among patients 627 "in denial". JAMA pyschiatry. 2015; 72(4): 303-304. 628 629 20. Chu HS, Oh J. Information needs and preferences of family caregivers of patients with 630 amyotrophic lateral sclerosis. Journal of Neuroscience Nursing. 2020; 52(5): 207-213. 21. Zimmermann C. Denial of impending death: A discourse analysis of the palliative care literature. 631 632 Social Science & Medicine. 2004; 59(8): 1769-1780. 22. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: Andersen 633 634 PM, Abrahams S, Borasio GD, de Carvalho M, Chio A, Damme PV, Hardiman O, Kollewe K, Morrison EK, Petri S, Pradat P, Silani V, Tomik B, Wasner M, Weber M. EFNS guidelines on the 635 clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. 636 Eur J Neurol. 2012;19(3):360-375. doi:10.1111/j.1468-1331.2011.03501.x 637 23. Brown J, Addington-Hall J. How people with motor neurone disease talk about living with their 638 illness. A narrative study. Journal of Advanced Nursing. 2008; 62(2): 200-208. 639 24. Miller RG, Jackson CE, Kasarskis EJ, England JD, Forshew D, Johnston W. Practice parameter 640 update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom 641 management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality 642 Standards Subcommittee of the American. Neurology. 2009; 73(15): 1227-1233. 643 25. Bolmsjo I, Hermeren G. Interviews with patients, family, and caregivers in amyotrophic lateral 644 sclerosis: Comparing needs. Journal of palliative care. 2001; 17(4): 236. 645 26. Astrow AB, Sood JR, Nolan MT, Terry PB, Clawson L, Kub J, et al. Decision-making in patients 646 with advanced cancer compared with amyotrophic lateral sclerosis. Journal of Medical Ethics. 2008; 647 648 34(9): 664-668. 27. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the 649 diagnosis of amyotrophic lateral sclerosis. Amytrophic lateral sclerosis and other motor neuron 650 651 disorders. 2000; 1(5): 293-299. 28. Soriani MH, Desnuelle C. Care management in amyotrophic lateral sclerosis. Revue 652 neurologique. 2017; 173(5): 288-299. 653 29. Canadian Institute for Health Information. Primary Health Care in Canada: A Chartbook of 654 Selected Indicator Results. [Online].; 2016. Available from: 655 https://secure.cihi.ca/estore/productFamily.htm?locale=en&pf=PFC3137. 656 657 30. Mitsumoto H, G. RJ. Palliative care for patients with amyotrophic lateral sclerosis: "Prepare for the worst and hope for the best". JAMA. 2007; 298(2): 207-216. 658 31. Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis: 659 660 Improving care with a multidisciplinary approach. Journal of multidisciplinary healthcare. 2017; 10: 205. 661 32. Mishler EG. The discourse of medicine: Dialectics of medical interviews New Jersey: Albex 662 Publishing Corporation; 1984. 663 33. Thompson-Hodgetts S, Labonte C, Mazumder R, Phelan S. Helpful or harmful? A scoping 664 review of perceptions and outcomes of autism diagnostic disclosure to others. Research in Autism 665 Spectrum Disorders. 2020; 77: 101596. 666 667 34. Buckman RA. Breaking bad news: The SPIKES strategy. Community Oncology. 2005; 2(2): 138-142. 668

- 35. McCluskey L, Casarett D, Siderowf A. Psychosocial adjustement to ALS: a longitudinal study.
 Amyotroph Lateral Scler Other Motor Neuron Disord. 2004; 5(3): 131-135.
 36. Connolly S, Galvin M, Hardiman O. End-of-life management in patients with amyotrophic lateral
- 672 sclerosis. Lancet Neurology. 2015; 14(4): 435-442.
 - 37. Shaw JM, Brown RF, Dunn SM. A qualitative study of stress and coping responses in doctors
 breaking bad news. Patient Education and Counseling. 2013; 91(2): 243-248.
 - 38. Schellenberg KL, Schofield SJ, Fang S, Johnston WS. Breaking bad news in amyotrophic lateral
 sclerosis: The need for medical education. Amyotrophic Lateral Sclerosis and Frontotemporal
 Degeneration. 2014; 15(1-2): 47-54.
- 39. Sparks L, Villagran MM, Parker-Raley J, Cunningham CB. A patient-centered approach to
 breaking bad news: Communication guidelines for health care providers. Journal of Applied
 Communication Research. 2007; 35(2): 177-198.
- 40. O'Brien MR, Whitehead B, Jack BA, Mitchell JD. From symptom onset to a diagnosis of
 amyotrophic lateral sclerosis/motor neuron disease (ALS/MND): Experiences of people with
 ALS/MND and family carers–a qualitative study. Amyotrophic Lateral Sclerosis. 2011; 12(2): 97104.
- 41. Sisk BA, Bluebond-Langner M, Wiener L, Mack J, Wolfe J. Prognostic Disclosures to Children.
 Pediatrics. 2016a; 138(3): 10.
- 42. Sisk B, Frankel R, Kodish E, Harry Isaacson J. The truth about truth-telling in American
 medicine: A brief history. The Permanente Journal. 2016b; 20(3): 74-77.
- 43. Marchildon GP. Health systems in transition: Canada: University of Toronto Press; 2013.
- 44. Ministry of Health and Long-Term Care. Preventing and managing chronic disease: Ontario's
 framework. [Online].; 2007. Available from:
- 692 http://www.health.gov.on.ca/en/pro/programs/cdpm/pdf/framework_full.pdf.
- 45. Creswell JW. Qualitative inquiry & research design: Choosing among five approaches. 2nd ed.
 Thousand Oaks, CA: Sage Publications, Inc.; 2007.
- 46. Crabtree BF, L. MW. Doing qualitative research. 2nd ed. Thousand Oaks, CA: Sage Publications,
 Inc; 1999.
- 697 47. Sofaer S. Qualitative methods: What are they and why use them? Health Services Research.
 698 1999; 34(5 Pt II): 1101.
- 48. Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic
 lateral sclerosis. Nature Reviews in Neurology. 2011; 7(11): 639-349.
- 49. Singh S, Wassenaar DR. Contextualising the role of the gatekeeper in social science research.
 South African Journal of Bioethics and Law. 2016; 9(1): 42-46.
- 50. Morse JM. Data were saturated. Qualitative health research; 25(5): 587-588.
- 51. Braun V, Clarke V. Using Thematic Analysis in psychology. Qualitative Research in Psychology.
 2006; 3(2): 77-101.
- 52. Charmaz K. Constructionism and the grounded theory method; 2008.
- 53. Baxter J, Eyles J. Evaluating qualitative research in social geography: establishing 'rigor' in –
 qualitative rigor in interview analysis. Royal Gerographical Society. 1997; 22: 505-525.
- 54. Hogden A, Greenfield D, Nugus P, Kiernan MC. What influences patient decision-making in
 amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives. Patient Prefer
 Adherence. 2012b; 6: 829-838.
- 55. Chio A, Montuschi A, Cammarosano S, De Mercanti S, Cavallo E, Ilardi A, et al. ALS patients
 and caregivers communication preferences and information seeking behaviour. European Journal of
 Neurology. 2008; 15(1): 55-60.
- 56. Daraz L, Morrow AS, Ponce OJ, Beuschel B, Farah MH, Katabi A, et al. Can Patients Trust

- Online Health Information? A Meta-narrative Systematic Review Addressing the Quality of Health
 Information on the Internet. Journal of general internal medicine. 2019; 34(9): 1884-1891.
- 57. Abdulla S, Vielhaber S, Machts J, Heinze HJ, Dengler R, Petri S. Information needs and
- information-seeking preferences of ALS patients and their carers. Amyotrophic Lateral Sclerosis and
 Frontotemporal Degeneration. 2014; 15(7-8): 505-512.
- 58. Chio A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, et al. Global
- epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature.
 Neuroepidemiology. 2013; 41(2): 118-130.
- 59. Plage S, Olson RE. Surprise Reveals the Affective-Moral Economies in Cancer Illness
- 725 Narratives. Qual Health Res. 2021; 31(14): 2730-2742.
- 60. Marin B, Fontana A, Arcuti S, Copetti M, Boumediene F, Couratier P, et al. Age-specific ALS
- incidence: A dose-response meta-analysis. Eur J Epidemiol. 2018; 33(7): 621-634.